Condition: Myasthenia Gravis · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's immune system mistakenly attacks and damages the connection between nerves and muscles causing muscle weakness).
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| Neurology Center of North Orange County | Fullerton, California, United States | Recruiting |
| The Neurology Group | Pomona, California, United States | Recruiting |
| Advanced Neurology of Colorado | Fort Collins, Colorado, United States | Recruiting |
| University of Connecticut | Farmington, Connecticut, United States | Recruiting |
| SFM Clinical Research LLC | Boca Raton, Florida, United States | Recruiting |
| HSHS St. Elizabeth's Hospital | O'Fallon, Illinois, United States | Recruiting |
| Josephson Wallack Munshower Neurology, PC | Indianapolis, Indiana, United States | Recruiting |
| Tulane Center for Clinical Research | New Orleans, Louisiana, United States | Recruiting |
| Henry Ford Hospital | Detroit, Michigan, United States | Recruiting |
| Velocity Clinical Research, Inc. | Raleigh, North Carolina, United States | Recruiting |
| Atrium Health Wake Forest Baptist | Winston-Salem, North Carolina, United States | Recruiting |
| Texas Neurology | Dallas, Texas, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07217587